Annual General Meeting of Active Biotech AB
May 27 2016 - 02:33AM
The Annual General Meeting of Active Biotech was held on May 26,
2016.
In accordance with the Board of Directors' proposal, it was
resolved that no dividend would be paid.
The board members and the managing director were discharged from
liability with respect to their management of the company for
2015.
In accordance with the Election Committee's
proposal, the Board members Mats Arnhög, Magnhild
Sandberg-Wollheim, Peter Sjöstrand and Peter Thelin were
re-elected. The Meeting also resolved to re-elect Mats Arnhög as
Chairman of the Board. KPMG AB was re-elected as auditor.
Furthermore, in accordance with the Election Committee's
proposal, the Meeting resolved that the Election Committee shall be
composed of representatives for the three largest owners, as per
the end of September, 2016, as well as the Chairman of the
Board.
The Meeting approved the Board's proposal concerning guidelines
for remuneration to the President and other senior executives. The
guidelines conform to the principles applied to
date.
In accordance with the Board's proposal, the Meeting resolved to
authorize the Board, for a period that does not extend past the
date of the next Annual General Meeting, to resolve on the issue of
not more than seven million new shares and/or convertibles with the
corresponding dilution effect, with or without pre-emptive rights
for the company's shareholders.
Lund, May 27, 2016
Active Biotech AB (publ)Tomas LeandersonPresident and CEO
For further information, please contact:Hans Kolam,
CFOTel +46 46 19 20 44
Active Biotech AB (publ) (Nasdaq
Stockholm: ACTI) is a biotechnology company with focus on
neurodegenerative/inflammatory diseases and cancer. Laquinimod, an
orally administered small molecule with unique immunomodulatory
properties, is in pivotal Phase 3 development for the treatment of
relapsing remitting multiple sclerosis. Also, laquinimod is in
Phase 2 development for the treatment of primary progressive
multiple sclerosis and Huntington's disease. Furthermore,
commercial activities are conducted for the tasquinimod, SILC,
ANYARA and paquinimod projects. Please visit www.activebiotech.com
for more information.
Active Biotech AB(Corp. Reg. No. 556223-9227)Box
724, SE-220 07 Lund, SwedenTel: +46 (0)46 19 20 00
Active Biotech is obligated to publish the information contained
in this press release in accordance with the Swedish Securities
Market Act and/or the Financial Instruments Trading Act . This
information was provided to the media for publication at 8:30 a.m.
CET on May 27, 2016.
160527_Årsstämma_2016_Eng
http://hugin.info/1002/R/2015738/747453.pdf
HUG#2015738
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Mar 2023 to Mar 2024